ArticleScientific reports2026
Urinary 6-sulfatoxymelatonin as a predictive biomarker for brain injury in very preterm infants.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Brain injury in preterm infants (BIPI) remains a significant clinical challenge with limited diagnostic biomarkers. This study aimed to investigate urinary 6-sulfatoxymelatonin (6-SMT) levels as a potential noninvasive biomarker for brain injury in very preterm infants. A prospective cohort study was conducted with 127 very preterm infants admitted to our hospital from January to December 2024. Infants were categorized into brain-injury and control group based on neuroimaging findings. Urinary 6-SMT concentrations were measured on postnatal days 1, 3, and 7 using ELISA. Clinical parameters and perinatal risk factors were evaluated. Receiver operating characteristic (ROC) curve analysis was used to assess diagnostic efficacy, and conditional logistic regression analysis was performed to evaluate the association between urinary 6-SMT levels and brain injury. Compared with the control group (n = 97), infants with brain injury (n = 30) exhibited significantly lower gestational age (GA: 29.36 vs. 30.43 weeks, p = 0.028) and birth weight (BW: 1.21 vs. 1.34 kg, p = 0.030), significantly lower rates of acidosis (10.0% vs. 12.4%, p = 0.023) and antenatal magnesium sulfate (MgSO₄) exposure (30.0% vs. 60.8%, p = 0.003), and significantly higher rates of early infection (46.7% vs. 21.6%, p = 0.007) and asphyxia (30.0% vs. 1.0%, p = 0.014). Crucially, urinary 6-SMT levels were markedly lower in the brain injury group on all measurement days (day 1: 558.51 vs. 813.86 pg/mL, p = 0.015; day 3: 722.62 vs. 938.48 pg/mL, p < 0.001; Day 7: 796.81 vs. 1034.48 pg/mL, p = 0.014). ROC analysis identified day 3 urinary 6-SMT (cut-off 762.46 pg/mL) as the best single marker (AUC = 0.714, sensitivity 73.2%, specificity 70.0%), while a combined model integrating levels from days 1, 3, and 7 achieved superior diagnostic performance (AUC = 0.764, sensitivity 78.4%, specificity 66.7%). Urinary 6-SMT levels progressively increased during the first postnatal week and correlated positively with GA and BW on days 1 and 3, but correlations weakened by day 7. After 1:1 matching on GA and BW, conditional logistic regression analysis confirmed a significant protective association between higher day 3 urinary 6-SMT levels and reduced brain injury risk (adjusted OR = 0.996, p = 0.004). Reduced urinary 6-SMT concentrations in very preterm neonates are significantly associated with brain injury. Serial urinary 6-SMT measurements, particularly when combined across multiple time points, demonstrate promising diagnostic potential as a noninvasive biomarker for BIPI. These findings suggest that melatonin deficiency may contribute to the pathophysiology of preterm brain injury and warrant further investigation for clinical translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.